Effectiveness of ustekinumab and improvement in real-world work productivity and associated indirect costs in patients with moderate-severe Crohn’s disease in the United States of America

Key Points

• This research aims to evaluate the impact of ustekinumab on work productivity and associated costs in patients with moderate to severe Crohn's disease.
• Comparison of work productivity costs between patients receiving ustekinumab and those not receiving it.
• Assessment of symptom reduction during ustekinumab treatment.
• Analysis of annual work productivity loss costs.
• Patients on ustekinumab showed lower mean annual work productivity loss costs.
• Reduced work impairment was evident in patients receiving ustekinumab.
• Significant improvement in symptom severity during treatment with ustekinumab.